Upadacitinib (Synonyms: ABT-494)

Name: Upadacitinib
Brand: MedChemExpress
SKU: HY-19569
Rating: 5.0 (26 reviews)

Cat. No.: HY-19569 Purity: 99.98%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.

For research use only. We do not sell to patients.

CAS No. : 1310726-60-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 26 publication(s) in Google Scholar

Other Forms of Upadacitinib:

Upadacitinib-¹⁵N,d₂ In-stock
Upadacitinib (Standard) In-stock
Upadacitinib-d₅ Get quote
Upadacitinib tartrate tetrahydrate Get quote

26 Publications Citing Use of MCE Upadacitinib

Flow Cytometry

ELISA

Cell Proliferation/Viability Assay

RT-PCR

: Upadacitinib purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2025 Sep 25:S0003-4967(25)04383-3. [Abstract]; PBLs isolated from healthy participants (n = 6) were pretreated with either vehicle control (0.01% DMSO) or JAK inhibitor Upadacitinib (1 µM, 100 nM, 10 nM) before LPS stimulation. Secreted IL-6 and IL-1β were measured by ELISA 48 hours post-stimulation.

: Upadacitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 29;16(1):6972. [Abstract]; Cell survival of SUM149 BRCA1-Mut and BRCA1-Rev cells transfected with a concentration range (nM) of ADAR1 siRNA in the context of exposure to the JAK/STAT pathway inhibitor Upadacitinib ( 32 µM).

: Upadacitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 26;15(1):7165. [Abstract]; Human melanoma cells pre-incubated with FDA-approved small molecule inhibitors targeting the type I interferon pathway mediators, TYK2 (Deucravacitinib) or JAK1 (Ruxolitinib or Upadacitinib (1 µM)), compared to no IFN-α treatment controls (gray bars), as determined by RT-qPCR and flow cytometry, respectively.

: Upadacitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 26;15(1):7165. [Abstract]; Mouse melanoma cells pre-incubated with FDA-approved small molecule inhibitors targeting the type I interferon pathway mediators, TYK2 (Deucravacitinib) or JAK1 (Ruxolitinib or Upadacitinib (1 µM)), compared to no IFN-α treatment controls (gray bars), as determined by RT-qPCR and flow cytometry, respectively.

: Upadacitinib purchased from MedChemExpress. Usage Cited in: Cell. 2024 Jan 4;187(1):44-61.e17. [Abstract]; Schematic of vehicle (Veh) or Upadacitinib (Upa) (2.5 mg/kg; administered intranasally; twice daily for four consecutive days) treatment of ALT-induced allergic lung inflammation in WT mice. Flow cytometry of lung tissue from vehicle- or upadacitinib-treated mice challenged with intranasal ALT. Shown are the frequencies of ILC2s and eosinophils.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All JAK Isoform Specific Products:

View All Isoforms

JAK1 JAK2 JAK3 Tyk2 JAK

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

JAK1

0.043 μM (IC₅₀)

JAK2

0.2 μM (IC₅₀)

JAK3

2.3 μM (IC₅₀)

Tyk2

4.7 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
Sf21	IC₅₀	120 nM Compound: 6	Inhibition of recombinant C-terminal His6-tagged human JAK2 kinase domain (808 to end residues) expressed in baculovirus-infected Sf21 cells in presence of 0.1 mM ATP Inhibition of recombinant C-terminal His6-tagged human JAK2 kinase domain (808 to end residues) expressed in baculovirus-infected Sf21 cells in presence of 0.1 mM ATP	[PMID: 31318208]
Sf9	IC₅₀	2304 nM Compound: 6	Inhibition of GST-fused recombinant human JAK3 catalytic domain (811-1103 residues) expressed in Sf9 cells in presence of 0.1 mM ATP Inhibition of GST-fused recombinant human JAK3 catalytic domain (811-1103 residues) expressed in Sf9 cells in presence of 0.1 mM ATP	[PMID: 31318208]
Sf9	IC₅₀	47 nM Compound: 6	Inhibition of GST-fused recombinant human JAK1 catalytic domain (845-1142 residues) expressed in Sf9 cells in presence of 0.1 mM ATP Inhibition of GST-fused recombinant human JAK1 catalytic domain (845-1142 residues) expressed in Sf9 cells in presence of 0.1 mM ATP	[PMID: 31318208]

In Vitro

In biochemical assays, Upadacitinib is 74-fold more selective for JAK-1 than for JAK-2 (which is involved in erythropoiesis) and 58-fold more selective for JAK-1 than for JAK-3 (which is involved in immunosurveillance)^[1]. The enhanced selectivity of Upadacitinib for JAK-1 over JAK-2 and JAK-3 may offer an improved benefit–risk profile in patients with RA range^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Upadacitinib (0.1-10 mg/kg; oral gavage; twice a day for 10 days) demonstrates efficacy in rat arthritis models^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Lewis rats (Rat adjuvant-induced arthritis model)^[3]
Dosage:	0.1, 0.3, 1, 3, 10 mg/kg
Administration:	Oral gavage; twice a day for 10 days
Result:	Inhibited disease pathology in rat adjuvant induced arthritis.

Clinical Trial

Molecular Weight

380.37

Formula

C₁₇H₁₉F₃N₆O

CAS No.

1310726-60-3

Appearance

Solid

Color

White to light yellow

SMILES

O=C(N1C[C@@H](CC)[C@@H](C2=CN=C3C=NC(NC=C4)=C4N32)C1)NCC(F)(F)F

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (262.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6290 mL	13.1451 mL	26.2902 mL
5 mM	0.5258 mL	2.6290 mL	5.2580 mL
10 mM	0.2629 mL	1.3145 mL	2.6290 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.75 mg/mL (7.23 mM); Clear solution
Protocol 2

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.75 mg/mL (7.23 mM); Clear solution
Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (4.39 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 4

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.67 mg/mL (4.39 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 5

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.67 mg/mL (4.39 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 6

Add each solvent one by one: 1% DMSO 99% Saline
Solubility: ≥ 0.55 mg/mL (1.45 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (280 KB) SDS (393 KB)

COA (255 KB) HNMR (257 KB) RP-HPLC (253 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Nakayamada S, et al. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs. 2016 Oct;30(5):407-419. [Content Brief]

[2]. J. Voss, et al. THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects. doi 10.1136/annrheumdis-2014-eular.3823.

[3]. Parmentier JM, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018 Aug 28;2:23. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6290 mL	13.1451 mL	26.2902 mL	65.7255 mL
	5 mM	0.5258 mL	2.6290 mL	5.2580 mL	13.1451 mL
	10 mM	0.2629 mL	1.3145 mL	2.6290 mL	6.5725 mL
	15 mM	0.1753 mL	0.8763 mL	1.7527 mL	4.3817 mL
	20 mM	0.1315 mL	0.6573 mL	1.3145 mL	3.2863 mL
	25 mM	0.1052 mL	0.5258 mL	1.0516 mL	2.6290 mL
	30 mM	0.0876 mL	0.4382 mL	0.8763 mL	2.1908 mL
	40 mM	0.0657 mL	0.3286 mL	0.6573 mL	1.6431 mL
	50 mM	0.0526 mL	0.2629 mL	0.5258 mL	1.3145 mL
	60 mM	0.0438 mL	0.2191 mL	0.4382 mL	1.0954 mL
	80 mM	0.0329 mL	0.1643 mL	0.3286 mL	0.8216 mL
	100 mM	0.0263 mL	0.1315 mL	0.2629 mL	0.6573 mL

Upadacitinib Related Classifications

Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Upadacitinib1310726-60-3ABT-494ABT494ABT 494JAKJanus kinaseJAK1orally activeautoimmuneInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Upadacitinib (Synonyms: ABT-494)

Customer Review

Other Forms of Upadacitinib:

Upadacitinib Related Antibodies

26 Publications Citing Use of MCE Upadacitinib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All JAK Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Upadacitinib Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Upadacitinib Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report